GLP1_NEW

GZR18 (bofanglutide) 30 mg injection

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

GZR18_SC_30MG_OTHER

Trials: 1
Participants in these arms: 27

All doses pooled: GZR18 (bofanglutide) injection
GZR18 (bofanglutide) 4.8 mg injection once weekly

Effects across outcomes

Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.

Condition	Outcome	Window	Versus	Effect (95% CrI)	SUCRA
Overweight or obesity without diabetes (adults)	Serious adverse events	longest follow-up	Placebo	HR 1.70 (0.06 to 63.32)	0.42

Trials

NCT06256536
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase Ib/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GZR18 Injection in Chinese Obese/Overweight Patients
2022 · 60 randomized · 35 weeks

GZR18 (bofanglutide) 30 mg injection

Related

Effects across outcomes

Trials